Editorial: safety and tolerability of rifaximin for IBS - more information is required; authors' reply

Aliment Pharmacol Ther. 2014 Jul;40(2):209. doi: 10.1111/apt.12837.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Female
  • Gastrointestinal Agents / adverse effects*
  • Humans
  • Irritable Bowel Syndrome / drug therapy*
  • Male
  • Rifamycins / adverse effects*

Substances

  • Gastrointestinal Agents
  • Rifamycins